Advice shifting away from using aspirin to prevent first heart attack or stroke
Older adults without heart disease shouldn’t take daily low-dose aspirin to prevent a first heart attack or stroke, an influential health guidelines group said in preliminary updated advice released Tuesday.
Bleeding risks for adults in their 60s and up who haven’t had a heart attack or stroke outweigh any potential benefits from aspirin, the U.S. Preventive Services Task Force said in its draft guidance.
For the first time, the panel said there may be a small benefit for adults in their 40s who have no bleeding risks. For those in their 50s, the panel softened advice and said evidence of a benefit is less clear.
The recommendations are meant for people with high blood pressure, high cholesterol, obesity or other conditions that increase their chances for a heart attack or stroke.
Regardless of age, adults should talk with their doctors about stopping or starting aspirin to make sure it’s the right choice for them, said task force member Dr. John Wong, a primary care expert at Tufts Medical Center in Boston.
“Aspirin use can cause serious harms, and risk increases with age,” he said.
A daily pill combining four cholesterol and blood pressure drugs taken with low-dose aspirin cut the risk of heart attacks, strokes and deaths by nearly a third.
If finalized, the advice for older adults would backtrack on recommendations the panel issued in 2016 for helping prevent a first heart attack and stroke, but it would be in line with more recent guidelines from other medical groups.
Doctors have long recommended daily low-dose aspirin for many patients who already have had a heart attack or stroke. The task force guidance does not change that advice.
The task force previously said a daily aspirin might also protect against colorectal cancer for some adults in their 50s and 60s, but the updated guidance says more evidence of any benefit is needed.
The guidance was posted online to allow for public comments until Nov. 8. The group will evaluate that input and then make a final decision.
The independent panel of disease prevention experts analyzes medical research and literature and issues periodic advice on measures to help keep Americans healthy. Newer studies and a reanalysis of older research prompted the updated advice, Wong said.
Aspirin is best known as a pain reliever but it is also a blood thinner that can reduce chances for blood clots. But aspirin also has risks, even at low doses — mainly bleeding in the digestive tract or ulcers, both of which can be life threatening.
Aspirin is a popular drug for people who’ve never had a heart attack or stroke and would like to keep it that way.
Dr. Lauren Block, an internist-researcher at Feinstein Institutes for Medical Research in Manhasset, N.Y., said the guidance is important because so many adults take aspirin even though they have never had a heart attack or stroke.
Block, who is not on the task force, recently switched one of her patients from aspirin to a cholesterol-lowering statin drug because of the potential harms.
The patient, 70-year-old Richard Schrafel, has high blood pressure and knows about his heart attack risks. Schrafel, president of a paperboard distribution business, said he never had any ill effects from aspirin, but he is taking the new preliminary guidance seriously.
Rita Seefeldt, 63, also has high blood pressure and took a daily aspirin for about a decade until her doctor told her two years ago to stop.
“He said they changed their minds on that,” recalled the retired elementary school teacher from Milwaukee. She said she understands that science evolves.
Wong acknowledged that the backtracking might leave some patients frustrated and wondering why scientists can’t make up their minds.
“It’s a fair question,” he said. “What’s really important to know is that evidence changes over time.”
Get our free Coronavirus Today newsletter
Sign up for the latest news, best stories and what they mean for you, plus answers to your questions.
You may occasionally receive promotional content from the Los Angeles Times.